John Mendelsohn - Merrimack Pharmaceuticals Insider

MACK -- USA Stock  

USD 5.22  0.08  1.51%

  Director
Dr. John Mendelsohn, M.D. is an Independent Director of the Company. He has served as a member of our board of directors since June 2012. Dr. Mendelsohn has served as the CoDirector of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center since September 2011. Dr. Mendelsohn also served as President of the MD Anderson Cancer Center from 1996 to August 2011. Prior to joining the MD Anderson Cancer Center, Dr. Mendelsohn was founding director of the cancer center at the University of California San Diego and served as Chairman of Medicine at Memorial SloanKettering Cancer Center from 1985 to 1996. Dr. Mendelsohn also currently serves as the L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy at the James A. Baker, III Institute for Public Policy. Dr. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions, which led to the discovery, development and eventual commercialization of the cancer therapy cetuximab
Age: 78  Director Since 2012      
617-441-1000  http://www.merrimack.com
Mendelsohn holds an M.D. from Harvard Medical School and a B.S. from Harvard College.

John Mendelsohn Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (64.63) % which means that it has lost $64.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (19.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Steven GoldmanDova Pharmaceuticals
2017
Stephen HoffmanDicerna Pharmaceuticals
2007
Patrick MachadoEndocyte
2018
Albert ChenChina Cord Blood Corporation
N/A
Michael BlaszykNantKwest
2015
Daniel KisnerDynavax Technologies Corporatio
2010
Natale RicciardiDynavax Technologies Corporatio
2013
Ann HanhamEndocyte
2004
Alain MunozAuris Medical Holding AG
2018
Peter KolchinskyDicerna Pharmaceuticals
2013
John ThomasNantKwest
2014
Dennis LangerDicerna Pharmaceuticals
2007
Dan KisnerDynavax Technologies Corporatio
2010
Dennis BrownDelMar Pharmaceuticals
2013
Erich MohrDelMar Pharmaceuticals
2017
James LoughlinEdge Therapeutics
2011
Kurt ContiEdge Therapeutics
2010
Mark ChenChina Cord Blood Corporation
N/A
Robert TothDelMar Pharmaceuticals
2013
Rosemary CraneEdge Therapeutics
2017
Jennifer WengChina Cord Blood Corporation
N/A

Entity Summary

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 72 people.Merrimack Pharmaceuticals (MACK) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Merrimack Pharmaceuticals Leadership Team

Robert Mulroy, CEO and President Executive Director and Member of Executive Committee
George Demetri, Director
Gary Crocker, Independent Chairman of the Board
Vivian Lee, Director
James Quigley, Director
Birgit Schoeberl, Head of Discovery
Richard Peters, President CEO, Principal Financial Officer, Director
Ulrik Nielsen, Chief Scientific Officer and Sr. VP of Research
John Mendelsohn, Director
John Green, Chief Accounting Officer, Controller
Ellen Forest, Head of Human Resources
Yasir AlWakeel, CFO and Head - Corporate Development
Edward Stewart, Sr. VP of Bus. Devel. and President of Merrimack Healthcare Solutions
Jean Franchi, CFO,Principal Financial Officer, Principal Accounting Officer, Treasurer
William Sullivan, Head of Fin. and Accounting and Treasurer
William Mcclements, Head of Corporate Operations
John Dineen, Director
Russell Ray, Director
Peter Laivins, Head of Devel.
Michael Porter, Independent Director
Geoffrey Grande, IR Contact Officer
Sergio Santillana, Chief Medical Officer

Stock Performance Indicators

Current Sentiment - MACK

Merrimack Pharmaceuticals Investor Sentiment
Most of Macroaxis users are now bullish on Merrimack Pharmaceuticals. What is your trading attitude regarding investing in Merrimack Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">